Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Erectile Dysfunction Sigmoid Colon Cancer Rectal Cancer | Drug: Udenafil | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment |
| Official Title: | Efficacy of Udenafil in Treatment of Erectile Dysfunction After Radical Resection for Sigmoid Colon and Rectal Cancer : a Randomized Controlled Trial |
- Improvement of erectile function using IIEF-5 (International Index of Erectile Function-5), SEP Q2, Q3 (Sexual Encounter Profile Q2,Q3), and GEQ (Global efficacy Question) [ Time Frame: at 4 weeks after enrollment ]
- Improvement of erectile function using IIEF-5, SEP Q2,Q3, and GEQ [ Time Frame: at 12 months after enrollment ]
| Enrollment: | 46 |
| Study Start Date: | March 2009 |
| Study Completion Date: | January 2012 |
| Primary Completion Date: | January 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Placebo
normal control group
|
Drug: Udenafil
oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
Other Name: Zydena®, Dong-A Pharmaceutical co., Ltd, Seoul, Korea
|
|
Experimental: Udenafil
oral administration of placebo for Udenafil (Dong-A Pharmaceutical co., Ltd, Seoul, Korea)
|
Drug: Udenafil
oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
Other Name: Zydena®, Dong-A Pharmaceutical co., Ltd, Seoul, Korea
|
Detailed Description:
Post-pelvic surgery erectile dysfunction is of much interest to those performing sigmoid colon and rectal cancer surgery and their patients. Erectile dysfunction has been recognized to develop from damage to pelvic parasympathetic nerve, which are especially vulnerable during anterior rectal dissection. There may be also a contribution of psychological factors from the presence of stoma and fear of recurrent cancer. Recently, several studies reported that erectile dysfunction after rectal excision for rectal cancer was completely reversed or satisfactorily improved using oral erectile dysfunction drugs. Udenafil is a new phosphodiesterase type 5 (PDE 5) inhibitor for erectile dysfunction. Prior studies have also demonstrated a selectivity profile for udenafil that is similar to Sildenafil (viagra®) and tadalafil (Cialis®). But unlike tadalafil (Cialis®), it does not significantly inhibit the PDE11 isozyme and not produce significant myalgia. back pain, or leg pain.
This prospective, randomized study was designed to evaluate the efficacy of Udenafil treatment in treatment of erectile dysfunction after radical resection for sigmoid colon and rectal cancer. In order to conduct this study, enrolled patients will be randomly attributed to Udenafil group or placebo group.
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 19 Years to 70 Years (Adult, Senior) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
• Male patients between 19-70 years old in good general health
- Patient willing to treat postoperative erectile dysfunction and participate in the study
- Patient who understands and accepts to sign the informed consent form
- Patient who received radical resection for sigmoid colon and rectal cancer. : erectile dysfunction was developed following operation, not preoperatively
- Scores of IIEF-5 measured at 12 months after surgery is 16 or less
Exclusion Criteria:
-
• Documented problem of preoperative erectile dysfunction
- Past history of myocardial infarction, cerebrovascular disease
- Under administration of nitrate
- Liver dysfunction (SGOT or SGPT 100 IU/L or more)
- Kidney dysfunction (serum Creatinine 3mg/dl or more)
Contacts and Locations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00607282
| Korea, Republic of | |
| Department of Surgery, Seoul National University Bundang Hospital | |
| Seongnam, Korea, Republic of, 463-707 | |
| Principal Investigator: | Sung-Bum Kang, M.D., Ph.D | Seoul National University Bundang Hospital |
More Information
| Responsible Party: | Sung-Bum Kang, Professor, Seoul National University Bundang Hospital |
| ClinicalTrials.gov Identifier: | NCT00607282 History of Changes |
| Other Study ID Numbers: |
B-0610-038-004 SNUBH-GS-CR2 |
| First Submitted: | January 22, 2008 |
| First Posted: | February 5, 2008 |
| Last Update Posted: | September 5, 2012 |
| Last Verified: | September 2012 |
Additional relevant MeSH terms:
|
Rectal Neoplasms Erectile Dysfunction Sigmoid Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases |
Sexual Dysfunction, Physiological Genital Diseases, Male Sexual Dysfunctions, Psychological Mental Disorders Colonic Neoplasms Colonic Diseases Sigmoid Diseases Udenafil Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |